Press Release

Zetagen Therapeutics, Inc. Receives Australian Patent Issuance for Treatment of Stimulating Bone Growth

23 July 2020

U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
Latest patent issuance furthers the Company’s Global IP strategy
Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions

July 23, 2020, (Syracuse, New York) - private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the Australian Government has issued Patent No. 2015267006 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using the Company’s small molecule, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

“This latest patent issuance lays the platform for our impending commercialization strategy to bring products like ZetaMet™ (Zeta-BC-003) to all continents with patients suffering from cancerous metastatic lesions,” said Joe C. Loy, CEO of Zetgen Therapeutics, Inc.

This patent follows the previously issued U.S. Patent No. 102656437 covering the use of methods to promote controlled bone creation and destruction as a means to heal large bone segmental defects and U.S. Patent No. 10208306 and South African PCT. 201700029 covering the use of a method for stimulating bone growth using a small molecule. The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions.

About Zetagen Therapeutics

Zetagen has three novel drugs in development with the Zeta Platform, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit www.zetagen.com. The entire Zeta platform is designed for intratumoral administration to reduce off-target toxicity, utilizing proprietary carriers—some incorporating our New Molecular Entity. The USPTO has granted Zetagen Composition-of-Matter patents and claims for all three therapeutics.

Zetagen Upcoming Events

Zetagen will attend the 2025 San Antonio Breast Cancer Symposium (SABCS) and the 2026 JP Morgan Healthcare Conference.

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.